Two-year results for I Ray System in Age-Related Macular Degeneration-Oraya

Oraya Therapeutics announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy using I Ray Radiotherapy for wet Age-Related Macular Degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. The study met primary and secondary endpoints and showed that Oraya Therapy (employing a low-voltage I Ray source with advanced robotics, a laser-guided positioning system, and eye stabilization and tracking) significantly reduces the need for anti-VEGF injections while maintaining vision in the presence of a favorable safety profile.

A total of 21 sites in five European countries participated in the trial. Two-year results showed that a broadly inclusive cohort of previously treated Wet AMD patients continued to receive the benefits of a 25 percent mean reduction in anti-VEGF injections over two years. Additionally, the targeted patient population maintained a 45 percent mean reduction in injections through two-year visit, with stable vision. Results were presented at a EURETINA seminar.